Related Experiment Video
Updated: May 27, 2026
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Identification and Validation of 3-Cyano-Quinoline Ligands Targeting Integrin-Linked Kinase (ILK)
Francesco Aleksy Greco1,2,3, Kamal Rayees Abdul Azeez1,2, Marko Mitrović1,2
1Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, Frankfurt am Main 60438, Germany.
Researchers identified novel 3-cyano-quinolines as the first validated ligands for integrin-linked kinase (ILK), a protein implicated in cancer. These potent ILK binders modulate cytoskeletal dynamics, paving the way for new cancer therapies.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Cell Biology
Background:
- Integrin-linked kinase (ILK) is a pseudokinase crucial for focal adhesion and implicated in cancer.
- No validated ligands for ILK have been previously reported, hindering therapeutic development.
Purpose of the Study:
- To identify and characterize novel small molecule ligands for ILK.
- To explore the structure-activity relationships (SAR) of identified ligands.
- To investigate the functional effects of ILK ligands on cellular processes.
Main Methods:
- High-throughput screening and binding assays to identify ILK ligands.
- Crystallographic studies to determine ligand binding modes.
- Parallel synthesis and medicinal chemistry for SAR exploration.
- Cell-based assays to assess modulation of actin cytoskeletal dynamics.
Main Results:
- Identification of 3-cyano-quinolines with potent binding affinity (KD ≈ 250 nM) to ILK.
- Crystallography revealed a type I binding mode for the identified ligands.
- Comprehensive SAR studies identified key modification sites.
- Optimized compound 1 (DHP) demonstrated modulation of actin cytoskeletal dynamics.
Conclusions:
- This study reports the first validated ILK ligands, specifically 3-cyano-quinolines.
- The findings provide a foundation for developing ILK-targeted therapeutics, including PROTACs for cancer treatment.
More Related Videos
11:11Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
